Latest / Community Health Media
Drs. Bill Gradishar, Tarah Ballinger, & Megan Kruse - HER2+ Metastatic Breast Cancer: Cleopatra, DESTINY-Breast09 & What Comes Next
For more than a decade, the Cleopatra regimen transformed outcomes in HER2-positive metastatic breast cancer — delivering landmark overall survival gains and redefining long-term disease control.
Recorded at SABCS, this expert roundtable features Dr. Bill Gradishar, Dr. Tarah Ballinger, and Dr. Megan Kruse as they examine how the HER2 landscape is evolving in the era of antibody–drug conjugates.
The discussion explores the real-world impact of DESTINY-Breast09, the role of trastuzumab deruxtecan (T-DXd) in the first-line setting, and how clinicians are balancing efficacy, toxicity, and…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.